TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05171179

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pecs blocks
Description: Pectoral nerve (Pecs) blocks I and II function by blocking the pectoral, intercostal, intercostobrachial nerves, and/or long thoracic nerve. These are used primarily for breast surgeries and are gaining momentum as simple administers of local analgesics. Pecs blocks utilize ultrasound to guide injection of local analgesic. It is less invasive and more accurate than most current modes of analgesia administration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pecs blocks
Description: Pectoral nerve (Pecs) blocks I and II function by blocking the pectoral, intercostal, intercostobrachial nerves, and/or long thoracic nerve. These are used primarily for breast surgeries and are gaining momentum as simple administers of local analgesics. Pecs blocks utilize ultrasound to guide injection of local analgesic. It is less invasive and more accurate than most current modes of analgesia administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Exparel is a sterile, non-pyrogenic white to off-white preservative-free aqueous suspension of multivesicular liposomes (DepoFoam® drug delivery system) containing bupivacaine. Bupivacaine is present at a concentration of 13.3 mg/mL. After injection of Exparel, bupivacaine is released from the multivesicular liposomes over a period of time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in arms 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in arms 2 and 3.

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine
Description: This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in arm 1.
Study: NCT03969693

Intervention type: RADIATION
Intervention: Standard treatment protocol with combined chemoradiation
Description: As for consolidative RT used in patients with early-stage Hodgkin lymphoma, the RT field must essentially include the mediastinum.
Study: NCT05844605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive neuromodulation (TMS and/or tDCS)
Description: Non-invasive neuromodulation (TMS and/or tDCS) coupled with intensive behavioural training (neurorehabilitation and/or cognitive rehabilitation)
Study: NCT05778110

Intervention type: OTHER
Intervention: Type of disease
Description: Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.

Intervention type: OTHER
Intervention: Type of disease
Description: Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.
Study: NCT05886660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPI-386 Nasal Gel
Description: Subjects will self-administer DPI-386 Nasal Gel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Gel
Description: Subjects will self-administer Placebo Nasal Gel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPI-386 Nasal Gel
Description: Subjects will self-administer DPI-386 Nasal Gel. Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Gel
Description: Subjects will self-administer Placebo Nasal Gel.~Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.
Study: NCT05947734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VTS surgical robotic system
Description: TheVTS surgical robotic system can accurately match the preoperative and intraoperative image data with the patient's anatomical structure on the operating table, track and locate the surgical instruments during the operation. With the help of the robotic arm, the surgeon can make the operation procedure more accurate and safer.
Study: NCT06560112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: ivgtt
Study: NCT05829733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNOLIS VA 80/160
Description: SYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg)
Study: NCT05829824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareConnect
Description: A combination of the Ask-Advise-Connect (AAC) with an Interactive Voice Response (IVR)

Intervention type: OTHER
Group type: OTHER
Intervention: AutoReach
Description: Phone call / SMS Text

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biospecimen samples
Description: Optional saliva sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen samples
Description: Optional saliva sample
Study: NCT05801484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid continuous infusion
Description: Continuous infusion of 1200 mg linezolid in 24h, after an initial dose of 600 mg linezolid administered as one hour infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Linezolid continuous infusion
Description: Continuous infusion of 1200 mg linezolid in 24h, after an initial dose of 600 mg linezolid administered as one hour infusion
Study: NCT05898607

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous Thoracic paravertebral block
Description: continuous infusion U/S-Guided TPVB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure intraoperative.
Study: NCT06031610

Intervention type: DRUG
Intervention: drug therapy
Description: Carotid artery stenosis requires taking antiplatelet aggregation drugs and statin lipid-lowering drugs. It can inhibit platelet aggregation, stabilize plaque, reduce vascular inflammatory factors, and prevent further development of atherosclerosis.
Study: NCT05197569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thyme oil
Description: Thyme oil with a carvacrol ratio of at least 74% will be specific to each patient and will be given to the patient in the form of an inhaler stick. According to expert opinion; The patient's own room should be visited every 8 hours and the patient-specific inhaler stick should be sniffed into 8 breathing lungs. Each patient will use an inhaler stick for 5 days. Hemodynamic parameters (ph, CO 2, O 2 ) and Covid-19 symptoms will be measured before the intervention with the patient (pretest) and at the end of the 5th day (posttest). Vital signs will be measured and recorded three times a day in the patient's room at 08:00, 16:00 and 24:00.
Study: NCT05833165

Intervention type: BEHAVIORAL
Intervention: Feasibility of a supportive approach
Description: Evaluating reasons for patients to use the approach
Study: NCT05048147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization
Description: The Community Mobilization (CM) strategy will include: (1) Community advisory board \[comprising local community-based organizations, government officials, and residents\], that will provide leadership support and buy-in for adoption of Clean Fuel- Clean- Stove (CF-CS) use; (2) Trained MoH community health extension workers, community health officers, community mobilizers and health education officers, who will form community action teams (CAT) to facilitate the implementation of CF-CS use via provision of support, knowledge exchange and performance feedback to the primary cooks in participating households; (3) Community dialogues with residents and households focused on shared concerns on the significance and importance of CF-CS use.
Study: NCT04850222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Subjects will be randomized to take Fluoxetine (10mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Subjects will be randomized to take Calcium supplementation (1000mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
Study: NCT06234293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: near-infrared light device
Description: Nurses will have to find the vein for the PIVC using the near-infrared light device.
Study: NCT05206084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)
Description: Subjects in this arm will be treated with IBS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
Description: Subjects in this arm will be treated with XIENCE
Study: NCT05396391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAP0971
Description: IAP0971 should be subcutaneous injected，q2w
Study: NCT06388733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Participants will receive niraparib 200 mg orally once daily starting on Day 1 of RT. Following completion of RT, participants will continue niraparib adjuvant therapy orally once daily on Days 1 to 28 of each 28-day cycle until progression by BICR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Participants randomized to the comparator arm (Arm B) will receive SOC TMZ 75 mg/m2 orally once daily with RT starting on Day 1 of RT. Following completion of RT, participants will complete a 4-week rest period, and then receive adjuvant TMZ 150 to 200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle until progression by BICR or for a maximum of 6 cycles.
Study: NCT06539052

Intervention type: DIAGNOSTIC_TEST
Intervention: anti-HDV positive with the reflex testing methodology
Description: Rate of screening for HBsAg in all migrants attending to one of the center participating to the project rate of screening for anti-Delta in all HBsAg patients identified rate of anti-Delta-positivity in HBsAg-positive subjects rate of linkage-to-care at one of the infectious disease center participating to the project rate of HDV-RNA testing in all anti-Delta positive subjects rate of treatment for HDV in all HDV-RNA-positive subjects Rate of screening for HIV Ab in all migrants attending to one of the center participating to the project Rate of screening for HCV Ab in all migrants attending to one of the center participating to the project.
Study: NCT05672849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Surgical Instruments/Devices (Sheaths and Irrigator)
Description: Patients who choose to undergo fetoscopic surgery will be offered participation in this study. All patients will undergo a fetoscopic repair of the fetal open neural tube defect with the use of the modified devices in this study.
Study: NCT04907370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 blocking antibody
Description: 1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT.~3. Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1
Study: NCT05252962

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Peptides
Description: Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Peptides
Description: Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Peptides
Description: Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
Study: NCT04907370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody
Description: 1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT.~3. Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin (80mg/m2)
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (80mg/m2)
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin (100mg/m2)
Description: Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
Study: NCT06362265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC.
Study: NCT05844566

Intervention type: DEVICE
Group type: OTHER
Intervention: Decision Support System (DSS)
Description: This DSS will provide estimates of potential benefits in terms of ASCVD risk reduction (composite endpoint: combined non-fatal myocardial infarction, non-fatal ischaemic stroke and cardiovascular death) as a function of treatment duration and magnitude of LDL-C lowering.~The DSS does not recommend treatments but shows the expected ASCVD risk, absolute and relative ASCDV risk reductions and number needed to treat for the various treatments selected by the clinical user on the potential value of initiation of an add-on therapy for reducing the risk of recurrent Cardiovascular (CV) events. Implementing the patient-specific recommendation remains at the clinicians' discretion.
Study: NCT05606406

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal Oxygen
Description: Nocturnal oxygen will be increased hourly for a period of four hours up to 4 liters per minute (LPM). If the oxygen saturation (SpO2) falls below 70% the oxygen rate will be increased until patients achieve the threshold of 70% and then will proceed with titrations of 1 liter per minute LPM per hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal Oxygen
Description: Nocturnal oxygen will be increased hourly for a period of four hours up to 4 liters per minute (LPM). If the oxygen saturation (SpO2) falls below 70% the oxygen rate will be increased until patients achieve the threshold of 70% and then will proceed with titrations of 1 liter per minute LPM per hour.
Study: NCT04385940

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ddrops® products, 50,000 IU, Oral
Description: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 1000IU
Study: NCT06502158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200 milligrams (mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 600 micrograms (ug)
Study: NCT05634408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management (A1D)
Description: TEST Lens
Study: NCT05969704

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI fusion targeted prostatic biopsy
Description: combines the pictures from an MRI and an ultrasound to create a detailed 3-D image of the prostate. This procedure makes it easier to see an abnormal lesion of prostate in order to guide the biopsy needle into the abnormal lesion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI cognitive targeted prostatic biopsy
Description: the biopsy operator reviews the MR images and creates a mental three-dimensional representation of the prostate and of the lesion within it to take a biopsy from the lesion
Study: NCT06338995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3650150
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3650150
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy for INCS
Description: Administered as intranasal spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy for INCS
Description: Administered as intranasal spray.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy for INCS
Description: Administered as intranasal spray.
Study: NCT06269913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FeSC
Description: Iron/yeast complex
Study: NCT06783244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intraabdominal pressure (8 mmHg)
Description: Only difference in treatment is the lower level of intraabdominal pressure by which the procedure is performed. The intervention does not change the treatment. The surgical procedure is performed due to Danish national guidelines and remains the same in the two arms.
Study: NCT06788665

Intervention type: DEVICE
Intervention: Medical Device Dermalyser
Description: Dermalyser is an Artificial Intelligence (AI) application (app) that allows medical professionals to take pictures of cutaneous lesions with the help of a smartphone camera. A dermatoscope is connected to the smartphone camera and is used to take the digital image of cutaneous lesions with suspicion of melanoma. Based on image processing algorithms, the app does a detailed analysis of the captured cutaneous lesion. In this clinical investigation, the objective is to test the device performance in a prospective setting in patients with a suspicion of primary cutaneous melanoma, to validate the added AI component. The intended purpose of the device is not to replace the physician's assessment, but rather to assist physicians in their assessment. Consequently, the final device should be regarded as a second opinion to augment clinical decision-making. The ultimate aim is to develop a tool that may augment clinical decision-making.
Study: NCT06788574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECAR device: MCRR. The sign producer is an INDIBA® 448 kHz RF device that has a vaginal/ or rectum electrode (made in Barcelona, Spain)
Description: TECAR (Transfer Electrical, Capacitive, and Resistive) is originally used in Italy. TECAR therapy is a radiofrequency (RF) therapy, which produces high-frequency waves. RF can be capacitive or resistive The capacitive mode (CET) generates energy in electrolyte-rich soft tissues such as muscles and vascular or lymphatic tissues . The resistive mode (RET) directs energy to deeper tissues that contain more fat and fibers (such as bones, ligaments, and tendons;

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: pelvic floor exercises
Description: pelvic floor exercise will be performed with the perineometer twice a week for eight weeks (16 sessions), with five sets of 20 repetitions each

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pelvic floor exercises
Description: pelvic floor exercise will be performed with the perineometer twice a week for eight weeks (16 sessions), with five sets of 20 repetitions each

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: sham treatment by Tecar device for 15 min without producing any waves.